SCHEMBL4282318

SCHEMBL4282318

FC(F)(F)c1ccc[c]c1CN1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 6/20 0.42
HIF1A Q16665 3/20 0.42
EPAS1 Q99814 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CXCR4 P61073 1/20 0.41
SLC2A1 P11166 1/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
ALOX15 P16050 3/20 0.38
CYP2C9 P11712 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP1A2 P05177 3/20 0.37
CYP2D6 P10635 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640828 0.85 CYP2A13 (0.42) CYP2A13ALDH1A1KMT2AMEN1CXCR4
SCHEMBL27083200 0.82 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1KDM4EATM
SCHEMBL2649768 0.80 CYP2A13 (0.57) CYP2A13ALDH1A1KMT2AMEN1CXCR4
SCHEMBL938713 0.79 KDM4E (0.40) CYP2A13HIF1AEPAS1ALDH1A1KMT2A
SCHEMBL14938678 0.77 CYP2A13 (0.57) CYP2A13ALDH1A1KMT2AMEN1CXCR4
SCHEMBL4282302 0.77 CYP2A13 (0.53) CYP2A13HIF1AEPAS1ALDH1A1KMT2A
SCHEMBL15859936 0.75 KDM4E (0.67) CYP2A13ALDH1A1KMT2AMEN1KDM4E
SCHEMBL2465608 0.74 CNR2 (0.45) HIF1AALDH1A1KMT2AMEN1KDM4E
SCHEMBL21408640 0.73 CYP3A4 (0.47) CYP2A13ALDH1A1KMT2AMEN1SLC2A1
SCHEMBL347002 0.73 LTA4H (0.39) ALDH1A1KDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137580-A1 Fused Heterocyclic Derivatives and Use Thereof TIE1, KDR, FLT1 CYP2A13 1775/4885HIF1A 179/4885EPAS1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.